Collegium Pharmaceutical Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Collegium Pharmaceutical Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Virginia
Headquarters city
Stoughton
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
COLL
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001267565

Board of directors

Follow this board

Chief executives

Vikram Karnani · President and CEO
Since November 2024
Joseph Ciaffoni · President and CEO
Until November 2024 · Former

Director election results

Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

10 of this board's directors also sit on 18 other boards.

Network of Collegium Pharmaceutical Inc.'s board connections Alkermes plc Alkermes plc Avalo Therapeutics Inc. Avalo Therapeutics Inc... Biohaven Ltd. Biohaven Ltd. COMPASS Pathways Plc COMPASS Pathways Plc Chemomab Therapeutics Ltd. American Depositary Share Chemomab Therapeutics... Dyne Therapeutics Inc. Dyne Therapeutics Inc. EyePoint Inc. EyePoint Inc. Gain Therapeutics Inc. Gain Therapeutics Inc. Indivior Pharmaceuticals Inc. Indivior Pharmaceutica... Karyopharm Therapeutics Inc. Karyopharm Therapeutic... Protalix BioTherapeutics Inc. (DE) Protalix BioTherapeuti... SI-BONE Inc. SI-BONE Inc. Standard BioTools Inc. Standard BioTools Inc. Sutro Biopharma Inc. Sutro Biopharma Inc. Trevi Therapeutics Inc. Trevi Therapeutics Inc... Vaxcyte Inc. Vaxcyte Inc. Carlos Paya V Carlos Paya V Garen G. Bohlin Garen G. Bohlin Gino Santini Gino Santini Gwen A. Melincoff Gwen A. Melincoff John Gordon Freund John Gordon Freund Joseph Ciaffoni Joseph Ciaffoni Michael Thomas Heffernan Michael Thomas Heffe... Nancy Lurker Nancy Lurker Vikram Karnani Vikram Karnani Collegium Pharmaceutical I...
Shared director Other board Same sector +2 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$7,244,675
14 sales by 8 insiders
Date Insider Transaction Shares Price Value
Jun 8, 2026 Gino Santini Director Option exercise +8,700 $16.49 $143,463
May 18, 2026 John Gordon Freund Director Open-market sale −20 $34.05 $681
May 15, 2026 John Gordon Freund Director Option exercise +8,700 $16.49 $143,463
May 15, 2026 John Gordon Freund Director Open-market sale −4,127 $34.54 $142,547
May 14, 2026 Donovan Michael Glancy Director Grant or award +17,482 — —
May 14, 2026 Nancy Lurker Director Grant or award +8,741 — —
May 14, 2026 Carlos Paya V Director Grant or award +8,741 — —
May 14, 2026 John Gordon Freund Director Grant or award +8,741 — —
May 14, 2026 Garen G. Bohlin Director Grant or award +8,741 — —
May 14, 2026 Rita J. Balice-Gordon Director Grant or award +8,741 — —
May 14, 2026 Gino Santini Director Grant or award +8,741 — —
May 13, 2026 Nancy Lurker Director Open-market sale −4,500 $35.97 $161,865
May 11, 2026 Garen G. Bohlin Director Option exercise +8,700 $16.49 $143,463
May 11, 2026 Garen G. Bohlin Director Open-market sale −8,700 $37.18 $323,466
Mar 18, 2026 Dieter David Officer (EVP & General Counsel) Open-market sale −13,976 $34.92 $488,042

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.